Molecular Cancer Therapeutics: 19 (3)

Selected Articles from This Issue

Selected Articles from This Issue

Selected Articles from This Issue

Mol Cancer Ther March 1 2020 19 (3) 729-729;

Small Molecule Therapeutics

Small Molecule Therapeutics

Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas

Long-Sheng Chang, Janet L. Oblinger, Sarah S. Burns, Jie Huang, Larry W. Anderson, Melinda G. Hollingshead, Rulong Shen, Li Pan, Garima Agarwal, Yulin Ren, Ryan D. Roberts, Barry R. O'Keefe, A. Douglas Kinghorn and Jerry M. Collins

Mol Cancer Ther March 1 2020 19 (3) 731-741; DOI:10.1158/1535-7163.MCT-19-0809
Small Molecule Therapeutics

Eribulin Suppresses Clear Cell Sarcoma Growth by Inhibiting Cell Proliferation and Inducing Melanocytic Differentiation Both Directly and Via Vascular Remodeling

Sho Nakai, Hironari Tamiya, Yoshinori Imura, Takaaki Nakai, Naohiro Yasuda, Toru Wakamatsu, Takaaki Tanaka, Hidetatsu Outani, Satoshi Takenaka, Kenichiro Hamada, Akira Myoui, Nobuhito Araki, Takafumi Ueda, Hideki Yoshikawa and Norifumi Naka

Mol Cancer Ther March 1 2020 19 (3) 742-754; DOI:10.1158/1535-7163.MCT-19-0358
Small Molecule Therapeutics | AuthorChoice

Macrophage Syk–PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk–PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression

Shweta Joshi, Kevin X. Liu, Muamera Zulcic, Alok R. Singh, Dylan Skola, Christopher K. Glass, P. Dominick Sanders, Andrew B. Sharabi, Timothy V. Pham, Pablo Tamayo, Daniel Shiang, Huy Q. Dinh, Catherine C. Hedrick, Guillermo A. Morales, Joseph R. Garlich and Donald L. Durden

Mol Cancer Ther March 1 2020 19 (3) 755-764; DOI:10.1158/1535-7163.MCT-19-0947
Small Molecule Therapeutics

Tankyrase Inhibitors Target Colorectal Cancer Stem Cells via AXIN-Dependent Downregulation of c-KIT Tyrosine Kinase

Myung-Kyu Jang, Tetsuo Mashima and Hiroyuki Seimiya

Mol Cancer Ther March 1 2020 19 (3) 765-776; DOI:10.1158/1535-7163.MCT-19-0668
Small Molecule Therapeutics

Preclinical Activity of Ribociclib in Squamous Cell Carcinoma of the Head and Neck

Gabrielle van Caloen, Sandra Schmitz, Mariama El Baroudi, Xavier Caignet, Sébastien Pyr dit Ruys, Pierre P. Roger, Didier Vertommen and Jean-Pascal Machiels

Mol Cancer Ther March 1 2020 19 (3) 777-789; DOI:10.1158/1535-7163.MCT-19-0695

Large Molecule Therapeutics

Large Molecule Therapeutics | AuthorChoice

Monoclonal Antibody Targeting Sialyl-di-Lewis^a–Containing Internalizing and Noninternalizing Glycoproteins with Cancer Immunotherapy Development Potential

Silvana T. Tivadar, Richard S. McIntosh, Jia Xin Chua, Robert Moss, Tina Parsons, Abed M. Zaitoun, Srinivasan Madhusudan, Lindy G. Durrant and Mireille Vankemmelbeke

Mol Cancer Ther March 1 2020 19 (3) 790-801; DOI:10.1158/1535-7163.MCT-19-0221
Large Molecule Therapeutics | AuthorChoice

Combination Immunotherapy with Cytotoxic T-Lymphocyte–Associated Antigen-4 and Programmed Death Protein-1 Inhibitors Prevents Postoperative Breast Tumor Recurrence and Metastasis

Ting Sun, Wenjia Zhang, Yuan Li, Zhengyu Jin, Yang Du, Jie Tian and Huadan Xue

Mol Cancer Ther March 1 2020 19 (3) 802-811; DOI:10.1158/1535-7163.MCT-19-0495
Large Molecule Therapeutics

Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity

Zeliang Zheng, Ryuhei Okada, Hisataka Kobayashi, Tadanobu Nagaya, Junxia Wei, Qi Zhou, Fred Lee, Tapan K. Bera, Yun Gao, William Kuhlman, Chin-Hsien Tai and Ira Pastan

Mol Cancer Ther March 1 2020 19 (3) 812-821; DOI:10.1158/1535-7163.MCT-19-0890
Large Molecule Therapeutics

Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies

Binbin Xie, Jianqin Wan, Xiaona Chen, Weidong Han and Hangxiang Wang

Mol Cancer Ther March 1 2020 19 (3) 822-834; DOI:10.1158/1535-7163.MCT-19-0625
Large Molecule Therapeutics | AuthorChoice

Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding

Robyn J. Puro, Myriam N. Bouchlaka, Ronald R. Hiebsch, Benjamin J. Capoccia, Michael J. Donio, Pamela T. Manning, William A. Frazier, Robert W. Karr and Daniel S. Pereira

Mol Cancer Ther March 1 2020 19 (3) 835-846; DOI:10.1158/1535-7163.MCT-19-1079

Cancer Biology and Translational Studies

Cancer Biology and Translational Studies

Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma

Melanie A. Krook, Alexandria Lenyo, Max Wilberding, Hannah Barker, Mikayla Dantuono, Kelly M. Bailey, Hui-Zi Chen, Julie W. Reeser, Michele R. Wing, Jharna Miya, Eric Samorodnitsky, Amy M. Smith, Thuy Dao, Dorrelyn M. Martin, Kristen K. Ciombor, John Hays, Aharon G. Freud and Sameek Roychowdhury

Mol Cancer Ther March 1 2020 19 (3) 847-857; DOI:10.1158/1535-7163.MCT-19-0631
Cancer Biology and Translational Studies | AuthorChoice

Extracellular Vesicle–Mediated In Vitro Transcribed mRNA Delivery for Treatment of HER2⁺ Breast Cancer Xenografts in Mice by Prodrug CB1954 without General Toxicity

Alexis V. Forterre, Jing-Hung Wang, Alain Delcayre, Kyuri Kim, Carol Green, Mark D. Pegram, Stefanie S. Jeffrey and A.C. Matin

Mol Cancer Ther March 1 2020 19 (3) 858-867; DOI:10.1158/1535-7163.MCT-19-0928
Cancer Biology and Translational Studies

Phosphodiesterase 3A Represents a Therapeutic Target that Drives Stem Cell–like Property and Metastasis in Breast Cancer

Na Hao, Wenzhi Shen, Renle Du, Shan Jiang, Junyong Zhu, Yanan Chen, Chongbiao Huang, Yi Shi, Rong Xiang and Yunping Luo

Mol Cancer Ther March 1 2020 19 (3) 868-881; DOI:10.1158/1535-7163.MCT-18-1233
Cancer Biology and Translational Studies

Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance

Tomohiro Shibata, Kosuke Watari, Akihiko Kawahara, Tomoya Sudo, Satoshi Hattori, Yuichi Murakami, Hiroto Izumi, Junji Itou, Masakazu Toi, Jun Akiba, Yoshito Akagi, Maki Tanaka, Michihiko Kuwano and Mayumi Ono

Mol Cancer Ther March 1 2020 19 (3) 882-894; DOI:10.1158/1535-7163.MCT-19-0690
Cancer Biology and Translational Studies

Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma

Karine Flem-Karlsen, Erin McFadden, Nasrin Omar, Mads H. Haugen, Geir Frode Øy, Truls Ryder, Hans Petter Gullestad, Robert Hermann, Gunhild Mari Mælandsmo and Vivi Ann Flørenes

Mol Cancer Ther March 1 2020 19 (3) 895-905; DOI:10.1158/1535-7163.MCT-19-0290
Cancer Biology and Translational Studies

PIN1 Inhibition Sensitizes Chemotherapy in Gastric Cancer Cells by Targeting Stem Cell–like Traits and Multiple Biomarkers

Zhen-Zhen Zhang, Wei-Xing Yu, Min Zheng, Xin-Hua Liao, Ji-Chuang Wang, Da-Yun Yang, Wen-Xian Lu, Long Wang, Sheng Zhang, He-Kun Liu, Xiao Zhen Zhou and Kun Ping Lu

Mol Cancer Ther March 1 2020 19 (3) 906-919; DOI:10.1158/1535-7163.MCT-19-0656
Cancer Biology and Translational Studies

Mechanisms of Entrectinib Resistance in a Neuroblastoma Xenograft Model

Suzanne P. MacFarland, Koumudi Naraparaju, Radhika Iyer, Peng Guan, Venkatadri Kolla, Yuxuan Hu, Kai Tan and Garrett M. Brodeur

Mol Cancer Ther March 1 2020 19 (3) 920-926; DOI:10.1158/1535-7163.MCT-18-1044

Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers

Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers

Genetic Interactions and Tissue Specificity Modulate the Association of Mutations with Drug Response

Dina Cramer, Johanna Mazur, Octavio Espinosa, Matthias Schlesner, Daniel Hübschmann, Roland Eils and Eike Staub

Mol Cancer Ther March 1 2020 19 (3) 927-936; DOI:10.1158/1535-7163.MCT-19-0045
Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers

Clinical Application of Next-Generation Sequencing–Based Panel to BRAF Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies

Changhee Park, Miso Kim, Min Jung Kim, Hyeongmin Kim, Chan-Young Ock, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Jong-Il Kim and Dae Seog Heo

Mol Cancer Ther March 1 2020 19 (3) 937-944; DOI:10.1158/1535-7163.MCT-19-0457
Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers

Genomic and Expression Analyses Define MUC17 and PCNX1 as Predictors of Chemotherapy Response in Breast Cancer

Waleed S. Al Amri, Lisa M. Allinson, Diana E. Baxter, Sandra M. Bell, Andrew M. Hanby, Stacey J. Jones, Abeer M. Shaaban, Lucy F. Stead, Eldo T. Verghese and Thomas A. Hughes

Mol Cancer Ther March 1 2020 19 (3) 945-955; DOI:10.1158/1535-7163.MCT-19-0940
Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers

KLF4 p.A472D Mutation Contributes to Acquired Resistance to Cetuximab in Colorectal Cancer

Song Ye, Xiaoge Hu, Chao Ni, Weiwei Jin, Yaping Xu, Lianpeng Chang, Huaixiang Zhou, Jiahong Jiang and Liu Yang

Mol Cancer Ther March 1 2020 19 (3) 956-965; DOI:10.1158/1535-7163.MCT-18-1385

Models and Technologies

Models and Technologies | AuthorChoice

Targeting Tumor Neoangiogenesis via Targeted Adenoviral Vector to Achieve Effective Cancer Gene Therapy for Disseminated Neoplastic Disease

Myungeun Lee, Zhi Hong Lu, Jie Li, Elena A. Kashentseva, Igor P. Dmitriev, Samir A. Mendonca and David T. Curiel

Mol Cancer Ther March 1 2020 19 (3) 966-971; DOI:10.1158/1535-7163.MCT-19-0768

Main menu

User menu

Search

Table of Contents

Selected Articles from This Issue

Small Molecule Therapeutics

Large Molecule Therapeutics

Cancer Biology and Translational Studies

Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers

Models and Technologies

Issue Highlights

Jump to

Articles

Info for

About MCT